Vedolizumab for ulcerative colitis and Crohn's disease: Results and implications of GEMINI studies

Immunotherapy

Volumn 6, Issue 9, 2014, Pages 963-971

  Lam, Mindy C W ^a   Bressler, Brian ^a  

^a Division of Gastroenterology   (Canada)

Author keywords

CD; Crohn's disease; GEMINI; UC; ulcerative colitis; VDZ; vedolizumab; 4 7 integrin

Indexed keywords

NATALIZUMAB; VEDOLIZUMAB; GASTROINTESTINAL AGENT; INTEGRIN; INTEGRIN ALPHA4BETA7; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; MAINTENANCE THERAPY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLITIS, ULCERATIVE; CONTROLLED STUDY; IMMUNOLOGY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INTEGRINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908127520     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.66     Document Type: Article

References (27)

1. Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1), 46-54 e42; quiz e30 (2012
2. Rivas MA, Beaudoin M, Gardet A et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat. Genet. 43(11), 1066-1073 (2011
3. Mokry M, Middendorp S, Wiegerinck CL et al. Many inflammatory bowel disease risk Loci include regions that regulate gene expression in immune cells and the intestinal epithelium. Gastroenterology 146(4), 1040-1047 (2014
4. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005
5. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002
6. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60(6), 780-787 (2011
7. Sandborn WJ, Van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2), 257-265 e25-253 (2012
8. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146(1), 85-95 quiz e14-15 (2013
9. Lang L. FDA approves Cimzia to treat Crohn's disease. Gastroenterology 134(7), 1819 (2008
10. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369(8), 699-710 (2013
11. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 369(8), 711-721 (2013
12. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7(9), 678-689 (2007
13. Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. mAbs 5(6), 842-850 (2013
14. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899-910 (2006
15. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 911-923 (2006
16. Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353(18), 1912-1925 (2005
17. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353(4), 375-381 (2005
18. Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353(4), 369-374 (2005
19. Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353(4), 362-368 (2005
20. US FDA. FDA Drug Safety Communication: safety update on progressive multifocal leukoencephalopathy (PML) associated with Tysabri (natalizumab) (20 January 2012). www.fda.gov/drugs/drugsafety/ucm288186.htm
21. TYSABRI® (natalizumab). Safety update on progressive multifocal leukoencephalopathy (PML) associated with Tysabri (natalizumab). FDA Drug Safety Communication 2013 (11 November 2012
22. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317(26), 1625-1629 (1987
23. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70(3), 439-444 (1976
24. Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147(3), 618-627.e3 (2014
25. Parikh A, Fox I, Leach T et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 19(8), 1691-1699 (2013
26. Haanstra KG, Hofman SO, Lopes Estevao DM et al. Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J. Immunol. 190(5), 1961-1973 (2013
27. Milch C, Wyant T, Xu J et al. Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J. Neuroimmunol. 264(1-2), 123-126 (2013